|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith RA, Manassaram-Baptiste D, Brooks D,
Doroshenk M, Fedewa S, Saslow D, Brawley OW and Wender R: Cancer
screening in the United States, 2015: A review of current American
cancer society guidelines and current issues in cancer screening.
CA Cancer J Clin. 65:30–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davalieva K, Kiprijanovska S, Komina S,
Petrusevska G, Zografska NC and Polenakovic M: Proteomics analysis
of urine reveals acute phase response proteins as candidate
diagnostic biomarkers for prostate cancer. Proteome Sci. 13(2)2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dihazi GH and Dihazi H: Protein-protein
interaction networks improve the proteomics data interpretation in
induced apoptosis. Expert Rev Proteomics. 7:177–180. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Mering C, Krause R, Snel B, Cornell M,
Oliver SG, Fields S and Bork P: Comparative assessment of
large-scale data sets of protein-protein interactions. Nature.
417:399–403. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xin-Yu Y and Zheng-Ping X: An introduction
to protein-protein interaction database and its application. Chin J
Biochem Mol Biol. 24:189–196. 2008.
|
|
7
|
Rakshit H, Rathi N and Roy D: Construction
and analysis of the protein-protein interaction networks based on
gene expression profiles of Parkinson's disease. PLoS One.
9:e1030472014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun J and Zhao Z: A comparative study of
cancer proteins in the human protein-protein interaction network.
BMC Genomics. 11(Suppl 3): S52010. View Article : Google Scholar
|
|
9
|
Lee SA, Tsao TT, Yang KC, Lin H, Kuo YL,
Hsu CH, Lee WK, Huang KC and Kao CY: Construction and analysis of
the protein-protein interaction networks for schizophrenia, bipolar
disorder, and major depression. BMC Bioinformatics. 12(Suppl 13):
S202011. View Article : Google Scholar
|
|
10
|
Ran J, Li H, Fu J, Liu L, Xing Y, Li X,
Shen H, Chen Y, Jiang X, Li Y, et al: Construction and analysis of
the protein-protein interaction network related to essential
hypertension. BMC Syst Biol. 7(32)2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davalieva K, Kostovska IM, Kiprijanovska
S, Markoska K, Kubelka-Sabit K, Filipovski V, Stavridis S, Stankov
O, Komina S, Petrusevska G and Polenakovic M: Proteomics analysis
of malignant and benign prostate tissue by 2D DIGE/MS reveals new
insights into proteins involved in prostate cancer. Prostate.
75:1586–1600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu CH, Yeh LS, Huang H, Arminski L,
Castro-Alvear J, Chen Y, Hu Z, Kourtesis P, Ledley RS, Suzek BE, et
al: The Protein Information Resource. Nucleic Acids Res.
31:345–347. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sardiu ME and Washburn MP: Building
protein-protein interaction networks with proteomics and
informatics tools. J Biol Chem. 286:23645–23651. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee S-A, Chan C-H, Chen T-C, Yang CY,
Huang KC, Tsai CH, Lai JM, Wang FS, Kao CY and Huang CY: POINeT:
Protein interactome with sub-network analysis and hub
prioritization. BMC Bioinformatics. 10(114)2009. View Article : Google Scholar
|
|
15
|
Saito R, Smoot ME, Ono K, Ruscheinski J,
Wang PL, Lotia S, Pico AR, Bader GD and Ideker T: A travel guide to
Cytoscape plugins. Nat Methods. 9:1069–1076. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeanquartier F, Jean-Quartier C and
Holzinger A: Integrated web visualizations for protein-protein
interaction databases. BMC Bioinformatics. 16(195)2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raman K: Construction and analysis of
protein-protein interaction networks. Autom Exp. 2(2)2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie W, Sun J and Wu J: Construction and
analysis of a protein-protein interaction network related to
self-renewal of mouse spermatogonial stem cells. Mol Biosyst.
11:835–843. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scardoni G, Petterlini M and Laudanna C:
Analyzing biological network parameters with CentiScaPe.
Bioinformatics. 25:2857–2859. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rhrissorrakrai K and Gunsalus KC: MINE:
Module identification in networks. BMC Bioinformatics. 12(192)2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lima-Mendez G and van Helden J: The
powerful law of the power law and other myths in network biology.
Mol Biosyst. 5:1482–1493. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xia J, Benner MJ and Hancock RE:
NetworkAnalyst - integrative approaches for protein-protein
interaction network analysis and visual exploration. Nucleic Acids
Res. 42:W167–W174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanz-Pamplona R, Berenguer A, Sole X,
Cordero D, Crous-Bou M, Serra-Musach J, Guinó E, Pujana MÁ and
Moreno V: Tools for protein-protein interaction network analysis in
cancer research. Clin Transl Oncol. 14:3–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jonsson PF and Bates PA: Global
topological features of cancer proteins in the human interactome.
Bioinformatics. 22:2291–2297. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu J and Li Y: Discovering disease-genes
by topological features in human protein-protein interaction
network. Bioinformatics. 22:2800–2805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanz-Pamplona R, Aragüés R, Driouch K,
Martín B, Oliva B, Gil M, Boluda S, Fernández PL, Martínez A,
Moreno V, et al: Expression of endoplasmic reticulum stress
proteins is a candidate marker of brain metastasis in both
ErbB-2+ and ErbB-2− primary breast tumors. Am
J Pathol. 179:564–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pujana MA, Han JD, Starita LM, Stevens KN,
Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, et al:
Network modeling links breast cancer susceptibility and centrosome
dysfunction. Nat Genet. 39:1338–1349. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sugita Y, Nakamura Y, Yamamoto M, Oda E,
Tokunaga O and Shigemori M: Expression of tubulin beta II in
neuroepithelial tumors: Reflection of architectural changes in the
developing human brain. Acta Neuropathol. 110:127–134. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ranganathan S, Salazar H, Benetatos CA and
Hudes GR: Immunohistochemical analysis of beta-tubulin isotypes in
human prostate carcinoma and benign prostatic hypertrophy.
Prostate. 30:263–268. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He ZY, Wen H, Shi CB and Wang J:
Up-regulation of hnRNP A1, Ezrin, tubulin β-2C and Annexin A1 in
sentinel lymph nodes of colorectal cancer. World J Gastroenterol.
16:4670–4676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chan CML, Wong SCC, Lam MYY, Hui EP, Chan
JK, Lo ES, Cheuk W, Wong MC, Tsao SW and Chan AT: Proteomic
comparison of nasopharyngeal cancer cell lines C666-1 and NP69
identifies down-regulation of annexin II and β2-tubulin for
nasopharyngeal carcinoma. Arch Pathol Lab Med. 132:675–683.
2008.PubMed/NCBI
|
|
33
|
Sejima T, Iwamoto H, Masago T, Morizane S,
Yao A, Isoyama T, Kadowaki H and Takenaka A: Low pre-operative
levels of serum albumin predict lymph node metastases and
ultimately correlate with a biochemical recurrence of prostate
cancer in radical pros-tatectomy patients. Cent European J Urol.
66:126–132. 2013.
|
|
34
|
Aparicio LM, Villaamil VM, Calvo MB,
Rubira LV, Rois JM, Valladares-Ayerbes M, Campelo RG, Bolós MV and
Pulido EG: Glucose transporter expression and the potential role of
fructose in renal cell carcinoma: A correlation with pathological
parameters. Mol Med Rep. 3:575–580. 2010. View Article : Google Scholar
|
|
35
|
Ito T, Noguchi Y, Satoh S, Hayashi H,
Inayama Y and Kitamura H: Expression of facilitative glucose
transporter isoforms in lung carcinomas: Its relation to histologic
type, differentiation grade, and tumor stage. Mod Pathol.
11:437–443. 1998.PubMed/NCBI
|
|
36
|
Shibata K, Kajiyama H, Ino K, Nawa A,
Nomura S, Mizutani S and Kikkawa F: P-LAP/IRAP-induced cell
proliferation and glucose uptake in endometrial carcinoma cells via
insulin receptor signaling. BMC Cancer. 7(15)2007. View Article : Google Scholar
|
|
37
|
Liu J, Wen D, Fang X, Wang X, Liu T and
Zhu J: p38MAPK signaling enhances glycolysis through the
up-regulation of the glucose transporter GLUT-4 in gastric cancer
cells. Cell Physiol Biochem. 36:155–165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Garrido P, Osorio FG, Morán J, Cabello E,
Alonso A, Freije JM and González C: Loss of GLUT4 induces metabolic
reprogramming and impairs viability of breast cancer cells. J Cell
Physiol. 230:191–198. 2015. View Article : Google Scholar
|
|
39
|
Won HJ, Ha TK, Kwon SJ, Cho HY, Hur SJ,
Baik HH, Suh SI, Ha E and Kim YH: Differential effects of
5-fluorouracil on glucose transport and expressions of glucose
transporter proteins in gastric cancer cells. Anticancer Drugs.
21:270–276. 2010. View Article : Google Scholar
|
|
40
|
Gonzalez-Menendez P, Hevia D,
Rodriguez-Garcia A, Mayo JC and Sainz RM: Regulation of GLUT
transporters by flavonoids in androgen-sensitive and -insensitive
prostate cancer cells. Endocrinology. 155:3238–3250. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fortier AM, Asselin E and Cadrin M:
Keratin 8 and 18 loss in epithelial cancer cells increases
collective cell migration and cisplatin sensitivity through
claudin1 up-regulation. J Biol Chem. 288:11555–11571. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Misra UK and Pizzo SV: Ligation of cell
surface GRP78 with antibody directed against the COOH-terminal
domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling
while promoting caspase activation in human prostate cancer cells.
Cancer Biol Ther. 9:142–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bakin RE, Gioeli D, Bissonette EA and
Weber MJ: Attenuation of Ras signaling restores androgen
sensitivity to hormone-refractory C4-2 prostate cancer cells.
Cancer Res. 63:1975–1980. 2003.PubMed/NCBI
|
|
44
|
Erlich S, Tal-Or P, Liebling R, Blum R,
Karunagaran D, Kloog Y and Pinkas-Kramarski R: Ras inhibition
results in growth arrest and death of androgen-dependent and
androgen-independent prostate cancer cells. Biochem Pharmacol.
72:427–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jia S, Gao X, Lee SH, Maira SM, Wu X,
Stack EC, Signoretti S, Loda M, Zhao JJ and Roberts TM: Opposing
effects of androgen deprivation and targeted therapy on prostate
cancer prevention. Cancer Discov. 3:44–51. 2013. View Article : Google Scholar :
|
|
46
|
Yin J, Pollock C, Tracy K, Chock M, Martin
P, Oberst M and Kelly K: Activation of the RalGEF/Ral pathway
promotes prostate cancer metastasis to bone. Mol Cell Biol.
27:7538–7550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mulholland DJ, Kobayashi N, Ruscetti M,
Zhi A, Tran LM, Huang J, Gleave M and Wu H: Pten loss and RAS/MAPK
activation cooperate to promote EMT and metastasis initiated from
prostate cancer stem/progenitor cells. Cancer Res. 72:1878–1889.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun C, Song C, Ma Z, Xu K, Zhang Y, Jin H,
Tong S, Ding W, Xia G and Ding Q: Periostin identified as a
potential biomarker of prostate cancer by iTRAQ-proteomics analysis
of prostate biopsy. Proteome Sci. 9(22)2011. View Article : Google Scholar
|
|
49
|
Pang J, Liu W-P, Liu X-P, Li LY, Fang YQ,
Sun QP, Liu SJ, Li MT, Su ZL and Gao X: Profiling protein markers
associated with lymph node metastasis in prostate cancer by
DIGE-based proteomics analysis. J Proteome Res. 9:216–226. 2010.
View Article : Google Scholar
|
|
50
|
Ummanni R, Junker H, Zimmermann U, Venz S,
Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F and
Walther R: Prohibitin identified by proteomic analysis of prostate
biopsies distinguishes hyperplasia and cancer. Cancer Lett.
266:171–185. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Alaiya AA, Al-Mohanna M, Aslam M, Shinwari
Z, Al-Mansouri L, Al-Rodayan M, Al-Eid M, Ahmad I, Hanash K, Tulbah
A, et al: Proteomics-based signature for human benign prostate
hyperplasia and prostate adenocarcinoma. Int J Oncol. 38:1047–1057.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Geisler C, Gaisa NT, Pfister D, Fuessel S,
Kristiansen G, Braunschweig T, Gostek S, Beine B, Diehl HC, Jackson
AM, et al: Identification and validation of potential new
biomarkers for prostate cancer diagnosis and prognosis using
2D-DIGE and MS. BioMed Res Int. 2015(454256)2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Skvortsov S, Schäfer G, Stasyk T,
Fuchsberger C, Bonn GK, Bartsch G, Klocker H and Huber LA:
Proteomics profiling of microdissected low- and high-grade prostate
tumors identifies Lamin A as a discriminatory biomarker. J Proteome
Res. 10:259–268. 2011. View Article : Google Scholar
|
|
54
|
Han ZD, Zhang YQ, He HC, Dai QS, Qin GQ,
Chen JH, Cai C, Fu X, Bi XC, Zhu JG, et al: Identification of novel
serological tumor markers for human prostate cancer using
integrative transcriptome and proteome analysis. Med Oncol.
29:2877–2888. 2012. View Article : Google Scholar : PubMed/NCBI
|
